Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal? (Q36338387)

13 August 2017

Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal? (English)

1 reference

13 August 2017

anti-retroviral agent

0 references

2

Douglas K Owens

1 reference

13 August 2017

3

Margaret L Brandeau

1 reference

13 August 2017

Diana M Negoescu

1

1 reference

PMCID

3478144

13 August 2017

Eran Bendavid

series ordinal

4

1 reference

PMCID

3478144

13 August 2017

language of work or name

English

0 references

publication date

31 August 2012

1 reference

Clinical Infectious Diseases

13 August 2017

1 reference

13 August 2017

55

1 reference

13 August 2017

10

1 reference

13 August 2017

1392-1399

1 reference

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Estimated HIV incidence in the United States, 2006-2009

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Deaths: final data for 2006.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Effect of early versus deferred antiretroviral therapy for HIV on survival

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

CD4+ count-guided interruption of antiretroviral treatment

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Hit HIV-1 hard, but only when necessary

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Time to hit HIV, early and hard.

30 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS731

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS731

Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS731

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS731

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS731

United States life tables, 2006.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3478144

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

22 September 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS731

Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS731

Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIS731

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22942203

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22942203

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22942203

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/CID/CIS731

1 reference

13 August 2017

1 reference

13 August 2017

1 reference

PMCID

3478144